Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

325.35 +3.29 (+1.02%)
Streaming Delayed Price Updated: 2:09 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 516,360
Open 319.62
Bid (Size) 325.10 (1)
Ask (Size) 325.60 (1)
Prev. Close 322.06
Today's Range 319.40 - 329.13
52wk Range 205.87 - 327.21
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alnylam Pharma Stock Outlook: Is ALNY Topping Out?
Alnylam Pharma Stock Outlook: For new entrants, chasing the momentum at this point would offer poor risk-reward dynamics. 
Via Benzinga
A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 9 Analysts
Via Benzinga

Performance

YTD
+39.3%
+39.3%
1 Month
+6.3%
+6.3%
3 Month
+27.2%
+27.2%
6 Month
+38.3%
+38.3%
1 Year
+33.7%
+33.7%

More News

Read More
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For May 1, 2025
Via Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Via Benzinga
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
From Instil Bio
Via GlobeNewswire
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case
Via Benzinga
Topics Intellectual Property
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today
Via Benzinga
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
Alnylam Issues 2024 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Via Benzinga
Topics World Trade
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount
Via The Motley Fool
BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
Via Investor's Business Daily

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?
Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market
What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?
The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 325.35
When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 07/02/25 02:09 PM ET
What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 38.67B
How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?
Alnylam Pharmaceuticals, Inc. - Common Stock has 39B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.